巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Myovant Sciences Ltd

    MYOV
    18.490
    0.790
    4.46%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Myovant Sciences Ltd - 延遲價格・最後更新於 12/08 9:30
    最高位
    18.840
    最低位
    17.870
    開市價
    --
    前收市價
    17.700
    成交量(千)
    26.22
    成交額(百萬)
    4.36
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    1,773.71
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    27.430 - 7.670
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Myovant Sciences Ltd
    證券代碼
    MYOV.US
    所屬板塊
    Biotechnology
    公司業務
    Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
    發行量
    93904902
    公司總部
    11-12 St. James’s Square, Suite 1, 3rd Floor
    公司網址
    https://www.myovant.com
    公司電郵
    investors@myovant.com
    公司電話
    +44 2074003351
    暫無內容

    關於

    Myovant Sciences Ltd(MYOV.US)所屬的行業板塊為Biotechnology。
    Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
    詳細公司背景可參考: https://www.myovant.com